por David Wallace. Durante años, la comunidad médica nos ha dicho lo mismo cuando se nos diagnostican neoplasias mieloproliferativas en fase inicial: «Vamos a esperar y observar». El razonamiento era sencillo: ¿por qué exponer a alguien a los efectos secundarios del tratamiento si aún no presenta síntomas? Sin embargo, un estudio publicado este diciembre en la revista Cancers está cuestionando todo ese […]
Paving the way to improve therapy for MPNs
Megan Bywater & Steven W. Lane, Nature Communications volume 13, Article number: 5025, Published: August 26, 2022 Long-acting IFNα induces durable molecular responses in myeloproliferative neoplasms. Emerging studies, including Saleiro et al. recently published in Nature Communications, have identified promising candidates that may synergize with IFNα by targeting stem cell function or feedback loops that mediate […]
Preclinical studies of Flonoltinib Maleate, novel JAK2/FLT3 inhibitor treatment for MPNs
Abstract Janus kinase 2 (JAK2) hyperactivation by JAK2V617F mutation leads to myeloproliferative neoplasms (MPNs) and targeting JAK2 could serve as a promising therapeutic strategy for MPNs. Here, we report that Flonoltinib Maleate (FM), a selective JAK2/FLT3 inhibitor, shows high selectivity for JAK2 over the JAK family. Surface plasmon resonance assays verified that FM had a stronger affinity […]
¿Se ha convertido la PV en una enfermedad de la mediana edad?
by David Wallace Dr. Ghaith Abu-Zeinah, Assistant Professor at Weill Cornell Medical College, Silver MPN Center is our MPN specialist answering this important question. David Wallace, PV Reporter, is your host and patient advocate. TRANSCRIPT | Has PV become a disease of the middle-aged? David: For many years PV been considered an older person’s disease. […]
Immunotherapy in Myeloproliferative Diseases
by Lukas M. Braun 1,2 and Robert Zeiser 1,3,4,5,* 1 Department of Medicine I, Medical Center—University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany; lukas.braun@uniklinik-freiburg.de 2 Faculty of Biology, University of Freiburg, 79104 Freiburg, Germany 3 German Cancer Consortium (DKTK) Partner Site Freiburg, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany 4 […]